BVF INC/IL - MOONLAKE IMMUNOTHERAPEUTICS ownership

MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 122 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q3 2023. The put-call ratio across all filers is 13.14 and the average weighting 1.0%.

Quarter-by-quarter ownership
BVF INC/IL ownership history of MOONLAKE IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2023$1,239,823,188
+11.8%
21,751,2840.0%33.43%
+8.1%
Q2 2023$1,109,315,484
+138.4%
21,751,2840.0%30.92%
+81.8%
Q1 2023$465,259,965
+103.7%
21,751,2840.0%17.01%
+76.4%
Q4 2022$228,388,482
+31.9%
21,751,2840.0%9.64%
+34.8%
Q3 2022$173,140,000
+51.6%
21,751,2840.0%7.15%
+29.7%
Q2 2022$114,194,00021,751,2845.52%
Other shareholders
MOONLAKE IMMUNOTHERAPEUTICS shareholders Q3 2023
NameSharesValueWeighting ↓
BVF INC/IL 21,751,284$1,239,823,18833.43%
Cormorant Asset Management, LP 8,142,100$464,099,70027.07%
Ally Bridge Group (NY) LLC 183,105$10,436,98512.25%
Finepoint Capital LP 331,416$18,890,7129.41%
Ghost Tree Capital, LLC 330,000$18,810,0006.19%
5AM Venture Management, LLC 313,210$17,852,9705.14%
Ghost Tree Capital, LLC 250,000$14,250,0004.69%
MPM BioImpact LLC 294,190$16,768,8304.48%
Integral Health Asset Management, LLC 500,000$28,500,0003.95%
Altium Capital Management LP 88,000$5,016,0002.62%
View complete list of MOONLAKE IMMUNOTHERAPEUTICS shareholders